BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today a progress update on its Biologics License Application (BLA) for valoctocogene...
Hank Fuchs Debra Charlesworth Traci Mccarty European Commission Drug Administration Biomarin Pharmaceutical Inc
Source: prnewswire.com